NCT02779855 2026-03-10
Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Completed
Clinical Trials
22 trialsNCT07102394 2026-02-17
Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1
Johns Hopkins University
Phase 1 Recruiting
NCT04599062 2026-01-29
TVEC and Preop Radiation for Sarcoma (8 ml Dose)
University of Iowa
Phase 1/2 Active not recruiting
NCT06660810 2026-01-15
Neoadjuvant Intralesional Injection of Talimogene Laherparepvec
University of Iowa
Phase 2 Active not recruiting
NCT03069378 2025-10-29
A Study of Talimogene Laherparepvec (T-VEC) in Combination With Pembrolizumab in Patients With Metastatic and/or Locally Advanced Sarcoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT03802604 2025-09-09
PROMETEO
SOLTI Breast Cancer Research Group
Phase EARLY_PHASE1 Completed
NCT03554044 2025-05-21
T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer
University of California, San Francisco
Phase 1 Completed
NCT03886311 2025-02-24
TNT
Sarcoma Oncology Research Center, LLC
Phase 2 Recruiting
NCT02819843 2025-01-29
A Study of T-VEC (Talimogene Laherparepvec) With or Without Radiotherapy for Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03663712 2024-11-20
TEMPO
Duke University
Phase 1 Completed
NCT02453191 2024-06-20
TVEC and Preop Radiation for Sarcoma (4 ml Dose)
University of Iowa
Phase 1/2 Completed
NCT03842943 2024-05-02
Neoadjuvant Combination Immunotherapy for Stage III Melanoma
University of Louisville
Phase 2 Recruiting
NCT04427306 2023-09-15
Neoadjuvant T-VEC in High Risk Early Melanoma
University of California, Davis
Phase 2 Suspended
NCT04185311 2023-08-15
Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted
Jonsson Comprehensive Cancer Center
Phase 1 Terminated
NCT02658812 2023-01-25
Talimogene Laherparepvec in Treating Patients With Recurrent Breast Cancer That Cannot Be Removed by Surgery
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT04065152 2022-06-10
KAPVEC
Assistance Publique - Hôpitaux de Paris
Phase 2 Unknown
NCT03458117 2022-03-18
20139157 T-VEC
University of Zurich
Phase 1 Completed
NCT03555032 2021-08-18
TITAN
Royal Marsden NHS Foundation Trust
Phase 1/2 Completed
NCT03597009 2021-04-20
A Study of Nivolumab and Intrapleural Talimogene Laherparepvec for Malignant Pleural Effusion
UNC Lineberger Comprehensive Cancer Center
Phase 1/2 Terminated
NCT03747744 2020-12-29
myDCTV
Universitair Ziekenhuis Brussel
Phase 1 Unknown
NCT03972046 2020-10-19
Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma
TriHealth Inc.
Phase 2 Withdrawn
NCT03088176 2020-10-12
Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma
West Cancer Center
Phase 1 Unknown